Daewoong Luncurkan Fexuprazan di Indonesia, Bawa Terapi P-CAB Generasi Baru untuk GERD

PT Daewoong Pharmaceutical Indonesia has officially launched fexuprazan in Indonesia, introducing a new generation of Potassium-Competitive Acid Blocker (P-CAB) therapy for patients suffering from gastroesophageal reflux disease (GERD).

The product launch took place on Friday, September 18, 2026, during the Indonesian Digestive Disease Week (IDDW) held at the Shangri-La Hotel in Jakarta. The event included a scientific symposium focused on the latest developments in P-CAB therapy and the presentation of clinical evidence regarding the treatment.

Article source: indoposco.id | Image credit: indoposco.id

News Desk: News Desk is the editorial publishing account for Tringlobe Media News, covering breaking news, public affairs, entertainment, community developments and regional stories across Trinidad and Tobago, the Caribbean and internationally.